United States · Platforms & data · The Motley Fool

Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

Published by The Motley Fool · United States 57 min ago

Detailed summary

Novo Nordisk's obesity-drug dominance faces rising rivals, while Pfizer's cheaper valuation and cash flow tell a different story for income-minded investors.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

MarketWatch

How Nvidia turmoil and a Democratic Congress could reshape the AI trade, according to ETF experts

TheStreet

Marvell’s 3 new directors hint at its biggest Lumentum risk

Morningstar

Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

Detailed summary

Share

Also worth reading

Budget airlines are going upscale with first-class seats and faster wifi

Amdocs director Yvette Kanouff acquires $100,800 in ordinary shares

Insider trades: Microsoft, Netflix, Boeing among notable names

How Nvidia turmoil and a Democratic Congress could reshape the AI trade, according to ETF experts

Marvell’s 3 new directors hint at its biggest Lumentum risk

Market News